CN104220068B - 包含奥美沙坦酯和罗苏伐他汀或其盐的药物组合物 - Google Patents

包含奥美沙坦酯和罗苏伐他汀或其盐的药物组合物 Download PDF

Info

Publication number
CN104220068B
CN104220068B CN201380018083.0A CN201380018083A CN104220068B CN 104220068 B CN104220068 B CN 104220068B CN 201380018083 A CN201380018083 A CN 201380018083A CN 104220068 B CN104220068 B CN 104220068B
Authority
CN
China
Prior art keywords
weight
olmesartan medoxomil
rosuvastatin
layer
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380018083.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN104220068A (zh
Inventor
张熙喆
姜复淇
金凖九
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daewoong Pharmaceutical Co Ltd
Original Assignee
Daewoong Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49260650&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN104220068(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Daewoong Pharmaceutical Co Ltd filed Critical Daewoong Pharmaceutical Co Ltd
Publication of CN104220068A publication Critical patent/CN104220068A/zh
Application granted granted Critical
Publication of CN104220068B publication Critical patent/CN104220068B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN201380018083.0A 2012-03-30 2013-03-22 包含奥美沙坦酯和罗苏伐他汀或其盐的药物组合物 Active CN104220068B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20120032903 2012-03-30
KR10-2012-0032903 2012-03-30
PCT/KR2013/002378 WO2013147462A1 (en) 2012-03-30 2013-03-22 Pharmaceutical composition comprising olmesartan medoxomil and rosuvastatin or its salt

Publications (2)

Publication Number Publication Date
CN104220068A CN104220068A (zh) 2014-12-17
CN104220068B true CN104220068B (zh) 2017-08-04

Family

ID=49260650

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380018083.0A Active CN104220068B (zh) 2012-03-30 2013-03-22 包含奥美沙坦酯和罗苏伐他汀或其盐的药物组合物

Country Status (22)

Country Link
US (1) US20150050333A1 (enExample)
EP (1) EP2830618B1 (enExample)
JP (1) JP6122098B2 (enExample)
KR (2) KR101451081B1 (enExample)
CN (1) CN104220068B (enExample)
AU (1) AU2013240846B2 (enExample)
CA (1) CA2866377C (enExample)
CL (1) CL2014002581A1 (enExample)
CY (1) CY1117909T1 (enExample)
DK (1) DK2830618T3 (enExample)
ES (1) ES2587912T3 (enExample)
HU (1) HUE030674T2 (enExample)
IN (1) IN2014MN01919A (enExample)
LT (1) LT2830618T (enExample)
MX (1) MX362400B (enExample)
MY (1) MY166288A (enExample)
PH (2) PH12014501813B1 (enExample)
PT (1) PT2830618T (enExample)
RU (1) RU2616516C2 (enExample)
SG (2) SG10201502582PA (enExample)
WO (1) WO2013147462A1 (enExample)
ZA (1) ZA201407544B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0752842Y2 (ja) 1989-10-04 1995-12-06 タカヤマ金属工業株式会社 樋支持具
EP3219318A4 (en) * 2014-11-11 2018-07-11 Shionogi & Co., Ltd. Multi-layered tablet containing drug unstable with respect to light
WO2016112389A1 (en) * 2015-01-09 2016-07-14 Autotelic Llc Methods for olmesartan dosing by auc
CN105395551A (zh) * 2015-11-19 2016-03-16 哈尔滨圣吉药业股份有限公司 一种奥美沙坦酯/瑞舒伐他汀复方制剂及其制备方法
CN106727580A (zh) * 2015-11-19 2017-05-31 哈尔滨圣吉药业股份有限公司 一种阿利沙坦酯/瑞舒伐他汀复方制剂及其制备方法
CN105232556A (zh) * 2015-11-19 2016-01-13 哈尔滨圣吉药业股份有限公司 一种坎地沙坦酯/瑞舒伐他汀复方制剂及其制备方法
CN105232555A (zh) * 2015-11-19 2016-01-13 哈尔滨圣吉药业股份有限公司 一种替米沙坦/瑞舒伐他汀复方制剂及其制备方法
CN106727579A (zh) * 2015-11-19 2017-05-31 哈尔滨圣吉药业股份有限公司 一种厄贝沙坦/瑞舒伐他汀复方制剂及其制备方法
TW201726744A (zh) 2016-01-11 2017-08-01 奧托德里克有限公司 用於檢測奧美沙坦(olmesartan)及改善治療高血壓之遵從性的組成物、裝置及方法
WO2018009842A1 (en) * 2016-07-08 2018-01-11 Autotelic Llc Methods for rosuvastatin dosing by auc
CN110913843B (zh) * 2017-07-17 2022-09-13 伊莱利利公司 药物组合物
KR101992400B1 (ko) * 2018-04-30 2019-06-24 보령제약 주식회사 약학적 제제
MX2021010183A (es) * 2019-02-26 2021-09-21 Daewoong Pharmaceutical Co Ltd Composicion farmaceutica con forma de dosificacion unica para tratar o prevenir la hipertension y la hiperlipidemia.
KR20220026641A (ko) * 2020-08-25 2022-03-07 주식회사 대웅제약 고혈압 및 고지혈증을 치료 또는 예방하기 위한 단일 제형의 약학 조성물
CN113398086A (zh) * 2021-05-18 2021-09-17 海南通用三洋药业有限公司 一种瑞舒伐他汀钙胶囊的制备方法和瑞舒伐他汀钙胶囊
CN113476423A (zh) * 2021-07-05 2021-10-08 海南通用三洋药业有限公司 一种瑞舒伐他汀钙胶囊的制备方法和瑞舒伐他汀钙胶囊

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008068217A2 (en) * 2006-12-04 2008-06-12 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising a coated hmg-coa reductase inhibitor and an inhibitor of the renin-angiotensin system
CN101478966A (zh) * 2006-06-27 2009-07-08 第一三共株式会社 压缩制剂

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1054019A1 (en) * 1999-05-18 2000-11-22 Shin-Etsu Chemical Co., Ltd. Low-substituted hydroxypropyl cellulose
JP2002145770A (ja) * 2000-08-30 2002-05-22 Sankyo Co Ltd 心不全の予防又は治療のための医薬組成物
US20110212175A1 (en) * 2006-10-30 2011-09-01 Hanall Biopharma Co., Ltd. Combination preparation comprising angiotensin-ii-receptor blocker and hmg-coa reductase inhibitor
MX2009004681A (es) * 2006-10-30 2009-08-19 Hanall Pharmaceutical Co Ltd Composicion compleja de liberacion controlada que comprende bloqueadores del receptor de angiotensina ii e inhibidores de hmg-coa-reductasa.
CN101594865A (zh) * 2006-12-07 2009-12-02 第一三共株式会社 含有低取代的羟基丙基纤维素的药物组合物
TWI488658B (zh) * 2006-12-26 2015-06-21 Daiichi Sankyo Co Ltd 溶出性之改善方法
TW200927197A (en) * 2007-10-29 2009-07-01 Daiichi Sankyo Co Ltd Film coated preparation
WO2009073683A2 (en) * 2007-12-04 2009-06-11 Schering Corporation Methods of treating copd
WO2009154810A2 (en) * 2008-02-25 2009-12-23 Dr. Reddy's Laboratories Ltd. Delivery systems for multiple active agents
WO2009113420A1 (ja) * 2008-03-13 2009-09-17 第一三共株式会社 オルメサルタンメドキソミルを含む製剤の溶出性の改善
KR20090114190A (ko) * 2008-04-29 2009-11-03 한올제약주식회사 방출성이 제어된 ＨＭＧ―ＣｏＡ 환원 효소 억제제와안지오텐신―Ⅱ―수용체 차단제의 복합 조성물
US10574932B2 (en) * 2008-07-28 2020-02-25 Fox Digital Enterprises, Inc. System and method of generating subtitling for media
CN102548544B (zh) * 2009-10-09 2015-01-21 永进药品工业株式会社 同时具有速效特性和长效特性的药物组合物
GB201003734D0 (en) * 2010-03-05 2010-04-21 Univ Strathclyde Delayed prolonged drug delivery
EP2438911A1 (en) * 2010-10-08 2012-04-11 LEK Pharmaceuticals d.d. Pharmaceuticals compositions comprising sulphonylurea-class insulin secretagogue and polyethylene glycol castor oil
US8399011B1 (en) * 2012-08-10 2013-03-19 Magnifica Inc. Oral particle compositions containing a core and an acid-soluble coat

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101478966A (zh) * 2006-06-27 2009-07-08 第一三共株式会社 压缩制剂
WO2008068217A2 (en) * 2006-12-04 2008-06-12 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising a coated hmg-coa reductase inhibitor and an inhibitor of the renin-angiotensin system

Also Published As

Publication number Publication date
MX362400B (es) 2019-01-16
KR20130111335A (ko) 2013-10-10
PH12016500420A1 (en) 2017-04-10
ES2587912T3 (es) 2016-10-27
RU2616516C2 (ru) 2017-04-17
ZA201407544B (en) 2015-12-23
PT2830618T (pt) 2016-11-04
CL2014002581A1 (es) 2015-01-09
DK2830618T3 (en) 2016-10-03
LT2830618T (lt) 2016-09-26
KR101451081B1 (ko) 2014-10-16
MX2014011510A (es) 2014-12-05
PH12014501813A1 (en) 2014-11-24
EP2830618A1 (en) 2015-02-04
SG11201405198YA (en) 2014-09-26
IN2014MN01919A (enExample) 2015-07-10
KR20140085411A (ko) 2014-07-07
AU2013240846A1 (en) 2014-08-28
CN104220068A (zh) 2014-12-17
PH12014501813B1 (en) 2014-11-24
WO2013147462A1 (en) 2013-10-03
EP2830618B1 (en) 2016-07-27
AU2013240846B2 (en) 2017-02-02
EP2830618A4 (en) 2015-08-05
CA2866377C (en) 2020-02-11
JP6122098B2 (ja) 2017-04-26
HUE030674T2 (en) 2017-06-28
CA2866377A1 (en) 2013-10-03
RU2014143536A (ru) 2016-05-27
KR101931195B1 (ko) 2018-12-21
JP2015511635A (ja) 2015-04-20
SG10201502582PA (en) 2015-05-28
MY166288A (en) 2018-06-25
CY1117909T1 (el) 2017-05-17
HK1200107A1 (en) 2015-07-31
US20150050333A1 (en) 2015-02-19

Similar Documents

Publication Publication Date Title
CN104220068B (zh) 包含奥美沙坦酯和罗苏伐他汀或其盐的药物组合物
EP1441713B1 (en) Modified release tamsulosin tablets
US20070059365A1 (en) Novel formulation of ropinirole
JP6068765B2 (ja) 薬学的複合製剤
KR20090114332A (ko) 약제학적 제제
WO2021129735A1 (zh) 一种固体制剂及其制备方法和用途
KR101907881B1 (ko) 로자탄, 암로디핀 및 히드로클로로티아자이드를 포함하는 고정 용량 조합 제형
JP6157740B2 (ja) 徐放性メトホルミンと速放性ＨＭＧ−ＣｏＡ還元酵素阻害剤を含む複合製剤
CN101472566A (zh) 阿利吉仑和氢氯噻嗪的盖仑制剂
JP2015503555A (ja) ボセンタン制御放出性経口製剤
ES2981599T3 (es) Composición farmacéutica de forma farmacéutica única para tratar o prevenir la hipertensión y la hiperlipidemia
TWI878600B (zh) 用於治療或預防高血壓及高膽固醇血症之單一劑型的醫藥組成物
US20050171119A1 (en) Pharmaceutical formulations with modified release
KR20090107960A (ko) 심혈관계 질환 치료용 약제학적 제제
KR102330953B1 (ko) 소듐-1-[6-(모르폴린-4-일)피리미딘-4-일]-4-(1h-1,2,3-트리아졸-1-일)-1h-피라졸-5-올레이트를 함유하는 제약 투여 형태
HK1200107B (en) Pharmaceutical composition comprising olmesartan medoxomil and rosuvastatin or its salt
WO2013050339A1 (en) Pharmaceutical compositions of antihypertensives
KR20150055986A (ko) 보센탄 제어방출성 경구제제
NZ760868B2 (en) A solid oral fixed dose composition comprising metformin, valsartan and atorvastatin
HK1216079B (en) Complex formulation containing sustained release metformin and immediate release hmg-coa reductase inhibitor

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1200107

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1200107

Country of ref document: HK